A sample text widget

Etiam pulvinar consectetur dolor sed malesuada. Ut convallis euismod dolor nec pretium. Nunc ut tristique massa.

Nam sodales mi vitae dolor ullamcorper et vulputate enim accumsan. Morbi orci magna, tincidunt vitae molestie nec, molestie at mi. Nulla nulla lorem, suscipit in posuere in, interdum non magna.

Roche Succeeds in Diabetes Drug

By comparing a weekly diabetes drug from Roche reduced blood sugar with other treatments across five late-stage clinical trials, there were found more positive data that adds to the potential blockbuster’s case for approval.

Roche, the world’s largest maker of cancer drugs, licensed taspoglutide from France’s Ipsen in 2006 and believes it can become a major seller in the so-called GLP-1 .

The experimental medicine showed benefits in all five Phase III trials, which compared it with current standards of care, including Eli Lilly and Amylin’s Byetta, Merck & Co’s Januvia and Lantus from Sanofi-Aventis.

In all five studies taspoglutide was generally well tolerated and the most frequently reported problems were nausea and vomiting.

VN:F [1.9.22_1171]
Rating: 0.0/10 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>